[HTML][HTML] CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer
YY Janjigian, J Bendell, E Calvo, JW Kim… - Journal of Clinical …, 2018 - ncbi.nlm.nih.gov
Purpose Metastatic esophagogastric cancer treatments after failure of second-line chemotherapy
are limited. Nivolumab demonstrated superior overall survival (OS) versus placebo in …
are limited. Nivolumab demonstrated superior overall survival (OS) versus placebo in …
CheckMate-032: phase I/II, open-label study of safety and activity of nivolumab (nivo) alone or with ipilimumab (ipi) in advanced and metastatic (A/M) gastric cancer …
4010 Background: Chemotherapy-refractory GC is a uniformly fatal illness and an unmet
therapeutic need. Nivo is a fully human anti-PD-1 monoclonal antibody with a manageable …
therapeutic need. Nivo is a fully human anti-PD-1 monoclonal antibody with a manageable …
First-in-human phase I trial of a tumor-targeted cytokine (NHS-IL12) in subjects with metastatic solid tumors
J Strauss, CR Heery, JW Kim, C Jochems… - Clinical Cancer …, 2019 - AACR
Purpose: The NHS-IL12 immunocytokine is composed of two IL12 heterodimers fused to the
NHS76 antibody. Preclinical studies have shown that this antibody targets IL12 to regions of …
NHS76 antibody. Preclinical studies have shown that this antibody targets IL12 to regions of …
Atezolizumab (MPDL3280A) monotherapy for patients with metastatic urothelial cancer: long-term outcomes from a phase 1 study
…, Y Loriot, R Morales-Barrera, HA Burris, JW Kim… - JAMA …, 2018 - jamanetwork.com
Importance Atezolizumab (anti–programmed death ligand 1) has demonstrated safety and
activity in advanced and metastatic urothelial carcinoma, but its long-term clinical profile …
activity in advanced and metastatic urothelial carcinoma, but its long-term clinical profile …
Safety and clinical activity of atezolizumab in patients with metastatic castration-resistant prostate cancer: a phase I study
…, P Conkling, JP Delord, M Gordon, JW Kim… - Clinical Cancer …, 2021 - AACR
Purpose: Atezolizumab [anti–programmed death-ligand 1 (anti-PD-L1)] is well tolerated and
efficacious in multiple cancers, but has not been previously evaluated in metastatic …
efficacious in multiple cancers, but has not been previously evaluated in metastatic …
Chemoprevention of head and neck cancer with green tea polyphenols
Recently, squamous cell carcinoma of the head and neck chemoprevention research has
made major advances with novel clinical trial designs suited for the purpose, use of …
made major advances with novel clinical trial designs suited for the purpose, use of …
First-in-class, first-in-human study evaluating LV305, a dendritic-cell tropic lentiviral vector, in sarcoma and other solid tumors expressing NY-ESO-1
N Somaiah, MS Block, JW Kim, GI Shapiro, KT Do… - Clinical Cancer …, 2019 - AACR
Purpose: LV305 is a modified, third-generation, nonreplicating, integration-deficient
lentivirus-based vector designed to selectively transduce dendritic cells in vivo. LV305 induces …
lentivirus-based vector designed to selectively transduce dendritic cells in vivo. LV305 induces …
Nivolumab±ipilimumab in pts with advanced (adv)/metastatic chemotherapy-refractory (CTx-R) gastric (G), esophageal (E), or gastroesophageal junction (GEJ) cancer …
4014 Background: In the phase 3 ONO-12 study, 3rd- or later-line nivolumab (N) monotherapy
prolonged OS vs placebo in Asian pts with adv G/GEJ cancer (median OS, 5.3 vs 4.1 mo; …
prolonged OS vs placebo in Asian pts with adv G/GEJ cancer (median OS, 5.3 vs 4.1 mo; …
[PDF][PDF] Prospects for targeting PD-1 and PD-L1 in various tumor types
JW Kim, JP Eder - Oncology, 2014 - Citeseer
Programmed death 1 (PD-1) is an immune inhibitory receptor expressed on several immune
cells, particularly cytotoxic T cells.[1] It interacts with two ligands, programmed death ligand …
cells, particularly cytotoxic T cells.[1] It interacts with two ligands, programmed death ligand …
Prospective study evaluating Na18F PET/CT in predicting clinical outcomes and survival in advanced prostate cancer
…, L Lindenberg, JH Shih, E Mena, JW Kim… - Journal of Nuclear …, 2016 - Soc Nuclear Med
This prospective pilot study evaluated the ability of Na 18 F PET/CT to detect and monitor
bone metastases over time and its correlation with clinical outcomes and survival in advanced …
bone metastases over time and its correlation with clinical outcomes and survival in advanced …